Literature DB >> 16187974

Allele and genotype frequencies of CYP2C9 in a Korean population.

Jung-Woo Bae1, Hyun-Kyung Kim, Ji-Hong Kim, Sang-In Yang, Mi-Jeong Kim, Choon-Gon Jang, Young-Seo Park, Seok-Yong Lee.   

Abstract

AIMS: To determine the frequencies of the variant alleles and the genotypes of CYP2C9 in a Korean population.
METHODS: Three hundred and fifty-eight healthy Korean subjects were studied. CYP2C9 alleles were detected by polymerase chain reaction-restriction fragment length polymorphism assays and direct sequencing assays.
RESULTS: The allele frequencies were 0.934 for CYP2C9*1, 0.060 for CYP2C9*3 and 0.006 for CYP2C9*13. The CYP2C9*2,*4,*5 and *11 alleles were not detected. The frequencies of the CYP2C9*1/*1, *1/*3 and *1/*13 genotypes were 0.869, 0.120 and 0.011, respectively.
CONCLUSION: The frequency of the CYP2C9*3 allele in the Korean population studied was significantly higher than reported elsewhere, and a novel allele, CYP2C9*13, was found at a frequency of 0.006 (95% confidence interval 0, 0.012). Only three genotypes of CYP2C9, CYP2C9*1/*1,*1/*3 and *1/*13 were observed in this Korean population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16187974      PMCID: PMC1884827          DOI: 10.1111/j.1365-2125.2005.02448.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

1.  Analysis of CYP2C9*5 in Caucasian, Oriental and black-African populations.

Authors:  Umit Yasar; Eleni Aklillu; Roberto Canaparo; Mia Sandberg; Jane Sayi; Hyung-Keun Roh; Agneta Wennerholm
Journal:  Eur J Clin Pharmacol       Date:  2002-11-01       Impact factor: 2.953

2.  Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.

Authors:  Maria Gabriella Scordo; Achille P Caputi; Concetta D'Arrigo; Giuseppina Fava; Edoardo Spina
Journal:  Pharmacol Res       Date:  2004-08       Impact factor: 7.658

3.  Discovery of new potentially defective alleles of human CYP2C9.

Authors:  Joyce Blaisdell; Lucia F Jorge-Nebert; Sherry Coulter; Stephen S Ferguson; Su-Jun Lee; Brian Chanas; Tina Xi; Harvey Mohrenweiser; Burhan Ghanayem; Joyce A Goldstein
Journal:  Pharmacogenetics       Date:  2004-08

4.  Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus.

Authors:  J Imai; I Ieiri; K Mamiya; S Miyahara; H Furuumi; E Nanba; M Yamane; Y Fukumaki; H Ninomiya; N Tashiro; K Otsubo; S Higuchi
Journal:  Pharmacogenetics       Date:  2000-02

5.  Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations.

Authors:  A Gaedigk; W L Casley; R F Tyndale; E M Sellers; M Jurima-Romet; J S Leeder
Journal:  Can J Physiol Pharmacol       Date:  2001-10       Impact factor: 2.273

Review 6.  Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

Authors:  Craig R Lee; Joyce A Goldstein; John A Pieper
Journal:  Pharmacogenetics       Date:  2002-04

7.  Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.

Authors:  G P Aithal; C P Day; P J Kesteven; A K Daly
Journal:  Lancet       Date:  1999-02-27       Impact factor: 79.321

8.  Identification of a novel variant CYP2C9 allele in Chinese.

Authors:  Dayong Si; Yingjie Guo; Yifan Zhang; Lei Yang; Hui Zhou; Dafang Zhong
Journal:  Pharmacogenetics       Date:  2004-07

9.  Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations.

Authors:  Jue Quin Yang; Sandrine Morin; Céline Verstuyft; Li An Fan; Yong Zhang; Chun Di Xu; Véronique Barbu; C Funck-Brentano; Patrice Jaillon; Laurent Becquemont
Journal:  Fundam Clin Pharmacol       Date:  2003-06       Impact factor: 2.748

Review 10.  Clinical relevance of genetic polymorphisms in the human CYP2C9 gene.

Authors:  U I Schwarz
Journal:  Eur J Clin Invest       Date:  2003-11       Impact factor: 4.686

View more
  28 in total

1.  Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups.

Authors:  Stuart A Scott; Rame Khasawneh; Inga Peter; Ruth Kornreich; Robert J Desnick
Journal:  Pharmacogenomics       Date:  2010-06       Impact factor: 2.533

2.  Comparison of genetic variation in drug ADME-related genes in Thais with Caucasian, African and Asian HapMap populations.

Authors:  Jiraphun Jittikoon; Surakameth Mahasirimongkol; Angkana Charoenyingwattana; Usa Chaikledkaew; Pramote Tragulpiankit; Supachoke Mangmool; Wimala Inunchot; Chayapol Somboonyosdes; Nuanjun Wichukchinda; Pathom Sawanpanyalert; Yijing He; Howard L McLeod; Wasun Chantratita
Journal:  J Hum Genet       Date:  2015-10-01       Impact factor: 3.172

3.  Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects.

Authors:  Yifan Zhang; Dayong Si; Xiaoyan Chen; Nan Lin; Yingjie Guo; Hui Zhou; Dafang Zhong
Journal:  Br J Clin Pharmacol       Date:  2007-02-12       Impact factor: 4.335

4.  In vitro functional characterization of 37 CYP2C9 allelic isoforms found in Chinese Han population.

Authors:  Da-peng Dai; Yu-han Wang; Shuang-hu Wang; Pei-wu Geng; Li-ming Hu; Guo-xin Hu; Jian-ping Cai
Journal:  Acta Pharmacol Sin       Date:  2013-09-30       Impact factor: 6.150

5.  Population pharmacokinetic analysis of glimepiride with CYP2C9 genetic polymorphism in healthy Korean subjects.

Authors:  Hee-Doo Yoo; Mi-Suk Kim; Hea-Young Cho; Yong-Bok Lee
Journal:  Eur J Clin Pharmacol       Date:  2011-04-08       Impact factor: 2.953

6.  Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics.

Authors:  Jung-woo Bae; Chang-ik Choi; Mi-jeong Kim; Da-hee Oh; Seul-ki Keum; Jung-in Park; Bo-hye Kim; Hye-kyoung Bang; Sung-gon Oh; Byung-sung Kang; Hyun-joo Park; Hae-deun Kim; Ji-hey Ha; Hee-jung Shin; Young-hoon Kim; Han-sung Na; Myeon-woo Chung; Choon-gon Jang; Seok-yong Lee
Journal:  Acta Pharmacol Sin       Date:  2011-08-15       Impact factor: 6.150

7.  Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients.

Authors:  Ramasamy Kesavan; Sunil K Narayan; Chandrasekaran Adithan
Journal:  Eur J Clin Pharmacol       Date:  2010-07       Impact factor: 2.953

8.  Pharmacogenetic distribution of warfarin and its clinical significance in Korean patients during initial anticoagulation therapy.

Authors:  Aerin Kwon; Sang-Ho Jo; Hyoung-June Im; Yun-A Jo; Ji-Young Park; Hee Jung Kang; Han-Sung Kim; Hyoun Chan Cho; Young Kyung Lee
Journal:  J Thromb Thrombolysis       Date:  2011-11       Impact factor: 2.300

9.  CYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects.

Authors:  Chang-Ik Choi; Mi-Jeong Kim; Eun-Kyung Chung; Hye-In Lee; Choon-Gon Jang; Jung-Woo Bae; Seok-Yong Lee
Journal:  Eur J Clin Pharmacol       Date:  2011-08-13       Impact factor: 2.953

10.  Cytochrome P450 2C9 (CYP2C9) polymorphisms in Chinese Li population.

Authors:  Yipeng Ding; Danlei Yang; Long Zhou; Ping He; Jinjian Yao; Pingdong Xie; Daobo Lin; Dingwei Sun; Pei Sun; Quanni Li; Tingting Geng; Tianbo Jin
Journal:  Int J Clin Exp Med       Date:  2015-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.